Skip to main content


In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants.

In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.

Suggested Citation

Institute of Medicine. 1995. Review of the Fialuridine (FIAU) Clinical Trials. Washington, DC: The National Academies Press.

Import this citation to:

Publication Info

280 pages |  8.5 x 11 | 

  • Paperback:  978-0-309-05279-5
  • Ebook:  978-0-309-17661-3
Chapters skim
Front Matter i-x
Executive Summary 1-15
Introduction 16-19
Clinical Trials 20-33
Hepatitis B and Other Viral Diseases 34-41
Clinical Trials of FIAC at Memorial Sloan-Kettering Cancer Center 42-50
Oclassen Clinical Trial R89-001-01 51-54
Oclassen Clinical Trial R90-001-01 (NIH Protocol 91-AI-0031) 55-60
Oclassen Clinical Trial R91-001-10 (NIH Protocol 91-DK-AI-213) 61-65
Eli Lilly Trial H3X-MC-PPPA 66-69
Eli Lilly Trial H3X-MC-PPPG 70-72
Eli Lilly Trial H3X-MC-PPPC (NIH Protocol 93-DK-0031) 73-89
Summary of Patient Interviews 90-92
Overall Assessment of the Trials 93-97
Recent Studies of FIAU Toxicity 98-103
Review of the FDA Task Force Report 'Fialuridine: Hepatic and Pancreatic Toxicity' 104-120
Review of 'Report to the Advisory Committee to the Director, National Institutes of Health' 121-132
FDA-Proposed Changes to the Code of Federal Regulations 133-142
Ancillary Issues Raised During the Period Following The H3X-MC-PPPC Trial 143-149
Conclusions and Recommendations 150-154
Appendix A: Chronology of FIAU/FIAC Clinical Trials 155-164
Appendix B: Bibliography and References 165-177
Appendix C: Agendas from the Three Committee Meetings 178-183
Appendix D: Informed Consent Documents 184-243
Appendix E: Example of Oclassen Fax Data Summaries 244-245
Appendix F: FIAC and FIAU Preclinical Toxicity Studies 246-250
Appendix G: Patient Summaries, Lilly Trial H3X-MC-PPPA 251-255
Appendix H: Statistical Analysis of Mortality in the FIAU/FIAC Clinical Trials 256-265
Glossary 266-269

What is skim?

The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.

Copyright Information

The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:

  • Republish text, tables, figures, or images in print
  • Post on a secure Intranet/Extranet website
  • Use in a PowerPoint Presentation
  • Distribute via CD-ROM
  • Photocopy

Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:

Rightslink Customer Care
Tel (toll free): 877/622-5543
Tel: 978/777-9929

To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.

To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.

loading iconLoading stats for Review of the Fialuridine (FIAU) Clinical Trials...